A resurrection of 7-MEOTA: a comparison with tacrine
Jazyk angličtina Země Spojené arabské emiráty Médium print
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
24093535
DOI
10.2174/1567205011310080011
PII: CAR-56335
Knihovny.cz E-zdroje
- MeSH
- cholinesterasové inhibitory farmakologie MeSH
- krysa rodu Rattus MeSH
- oxidační stres účinky léků MeSH
- potkani Wistar MeSH
- takrin analogy a deriváty farmakologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- 7-methoxytacrine MeSH Prohlížeč
- cholinesterasové inhibitory MeSH
- takrin MeSH
Alzheimer´s disease (AD) is a progressive neurodegenerative dementia which currently represents one of the biggest threats for the human kind. The cure is still unknown and various hypotheses (cholinergic, amyloidal, oxidative, vascular etc.) are investigated in order to understand the pathophysiology of the disease and on this basis find an effective treatment. Tacrine, the first approved drug for the AD disease treatment, has been reported to be a multitargeted drug, however it was withdrawn from the market particularly due to its hepatotoxicity. Its derivative 7-methoxytacrine (7- MEOTA) probably due to the different metabolization does not exert this side effect. The aim of our study was to compare these two cholinesterase inhibitors from various, mainly cholinergic, points of view relevant for a potential AD drug. We found that 7-MEOTA does not fall behind its more well-known parent compound - tacrine. Furthermore, we found, that 7-MEOTA exerts better properties in most of the tests related to a possible AD treatment. Only the pharmacokinetics and a higher acetylcholinesterase and butyrylcholinesterase inhibitory potency would slightly give advantages to tacrine over 7-MEOTA, but concerning its lower toxicity, better antioxidant properties, interaction with muscarinic and nicotinic receptors and "safer" metabolization provide strong evidence for reconsider 7-MEOTA and its derivatives as candidate molecules for the treatment of AD.
Citace poskytuje Crossref.org
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease
In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers
Technological Solutions for Older People with Alzheimer's Disease: Review
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy
Alzheimer's disease and language impairments: social intervention and medical treatment